Femme et Homme
- | Pays :
- Russian Federation
- Italy
- France
- Les 5 autres...
- | Organes : -
- | Spécialités : -
Extrait
This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive breast cancer. Patients received T-DM1 3.6 mg/kg intravenously on Day 1 of each 3-week cycle, for up to 17 cycles.
Critère d'inclusion
- Breast Cancer